OTCMKTS:ABCZY

Abcam - ABCZY Stock Forecast, Price & News

Add

Compare

Today's Range: N/A
50-Day Range: $19.40
▼
$19.40
52-Week Range: N/A

Volume: 5,400 shs
Average Volume: 4,712 shs
Market Capitalization: $3.98 billion

P/E Ratio: N/A
Dividend Yield: 0.36%
Price Target: N/A

About Abcam (OTCMKTS:ABCZY) Stock

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Receive ABCZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter.

ABCZY Stock News Headlines

March 30, 2023 | finance.yahoo.com

Abcam, plc Publication of 2022 Annual Report and Accounts and Notice of Annual General Meeting

February 6, 2023 | msn.com

Abcam unveils plaques honouring 41 scientists behind BRCA2 breast cancer gene discovery

April 1, 2023 | Vantage Point (Ad)

Did You See These Trend Reversals?

Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth.

November 9, 2022 | technews.tmcnet.com

NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research

October 17, 2022 | marketwatch.com

Abcam Seeks Approval to Cancel AIM Listing

September 29, 2022 | seekingalpha.com

Abcam: A Good Growth Stock In The Healthcare Market

September 14, 2022 | seekingalpha.com

Abcam ADS Non-GAAP EPS of 14.00p, revenue of £185.2M

September 12, 2022 | seekingalpha.com

Abcam plc (ABCM) Q4 2022 Earnings Call Transcript

April 1, 2023 | Vantage Point (Ad)

Did You See These Trend Reversals?

July 25, 2022 | investing.com

Abcam PLC PK (ABCZY)

July 20, 2022 | ft.com

Cambridge biotech Abcam to abandon London listing for Nasdaq

July 1, 2022 | uk.finance.yahoo.com

Are analysts upbeat on the outlook for Abcam?

March 25, 2022 | tmcnet.com

Abcam the most awarded company at 2022 industry awards

March 18, 2022 | nasdaq.com

Wall Street Analysts Predict a 27% Upside in Abcam PLC Sponsored ADR (ABCM): Here's What You Should Know

October 27, 2021 | lse.co.uk

Abcam completes acquisition of life science research tool distributor

August 2, 2021 | lse.co.uk

Abcam to buy BioVision for $340m

August 2, 2021 | uk.finance.yahoo.com

‘Amazon of antibodies’ Abcam buys up US supplier BioVision in $340million deal

August 2, 2021 | lse.co.uk

Abcam to acquire Boai NKY subsidiary BioVision for USD340 million

August 2, 2021 | marketwatch.com

Abcam to Buy BioVision for $340 Mln-- Deal Digest

August 2, 2021 | nasdaq.com

Abcam To Buy US-based BioVision For $340 Mln - Quick Facts

July 1, 2021 | marketwatch.com

Abcam Says Underlying Performance Has Been Modestly Ahead of Expectations

July 1, 2021 | lse.co.uk

Abcam trades in line with expectations as lab product demand limited

June 25, 2021 | ca.finance.yahoo.com

Some Shareholders May find It Hard To Increase Abcam plc's (LON:ABC) CEO Compensation This Year

April 12, 2021 | finance.yahoo.com

Abcam and MEDx extend precision medicine strategic partnership

March 4, 2021 | finance.yahoo.com

Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector

January 29, 2021 | finance.yahoo.com

Can You Imagine How Jubilant Abcam's (LON:ABC) Shareholders Feel About Its 164% Share Price Gain?

January 11, 2021 | lse.co.uk

Abcam Expects Good Interim Results As Most Regions Experience Growth

See More Headlines

Receive ABCZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Industrial Inorganic Chemicals
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ABCZY
Previous Symbol: NASDAQ:ABCZY
CUSIP: N/A
CIK: N/A
Web: www.abcam.com
Phone: 44 1223 696 000
Fax: N/A
Employees: 1,492
Year Founded: 1998

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $336.37 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 205,080,000
Free Float: N/A
Market Cap: $3.98 billion
Optionable: Not Optionable
Beta: 1.29

Social Links

Key Executives

Mr. Alan Thomas Hirzel BS (Age 52)
MS, MBA, CEO & Exec. Director

Mr. Michael Shaun Baldock (Age 54)
CFO & Director

Dr. Jonathan Simon Milner (Age 55)
Co-Founder & Non-Exec. Deputy Chairman

Mr. Mark Dermody
Interim CIO

James Staveley
VP of Investor Relations

Key Competitors

View All Competitors

ABCZY Stock - Frequently Asked Questions

Is Abcam a good dividend stock?: Abcam (OTCMKTS:ABCZY) pays an annual dividend of $0.07 per share and currently has a dividend yield of 0.36%.
Read our dividend analysis for ABCZY.
What is Abcam's stock symbol?: Abcam trades on the OTCMKTS under the ticker symbol "ABCZY."
How do I buy shares of Abcam?: Shares of ABCZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Abcam make?: Abcam (OTCMKTS:ABCZY) has a market capitalization of $0.00 and generates $336.37 million in revenue each year.
How many employees does Abcam have?: The company employs 1,492 workers across the globe.
Does Abcam have any subsidiaries?: The following companies are subsidiares of Abcam: Abcam (US) Ltd., Abcam Trading (Shanghai) Co. Ltd., Abcam US Group Holdings Inc., and Epitomics Inc.
Read More
How can I contact Abcam?: The official website for the company is www.abcam.com. The company can be reached via phone at 44 1223 696 000.

This page (OTCMKTS:ABCZY) was last updated on 4/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial